G15 antagonizes these beneficial effects.<h4>Conclusion</h4>Based on clinical data, this study shows that low GPER1 expression correlates closely with hepatic steatosis in MASLD. Here, GPER1 is linked to metabolic dysfunction-associated steatotic liver disease.